Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study

Table 1 The sample, n (%)

	Whole sample, n = 217		mEHT, n = 89		No-mEHT, n = 128		P value1
	Median	Range	Median	Range	Median	Range
Age (yr)	67	34-89	64	38-82	69	34-89	NS
Student’s test for proportions
M	122	56	58	65	64	50	NS
F	95	44	31	35	64	50	NS
Metastatic	142	65	70	79	72	56	0.004
Previous chemotherapy	136	63	68	76	68	53	0.005
Previous Radiotherapy	10	5	1	1	9	7	NS
Current chemotherapy type
Gemcitabine/oxaliplatin	76	35	34	38	42	33	NS
Gemcitabine	62	29	26	29	36	28	NS
Gemcitabine/abraxane	39	18	9	10	30	23	NS
Gemcitabine/5-fluorouracil	5	2	4	4	1	1	NS
Gemcitabine/cisplatin	10	5	2	2	8	6	NS
Gemcitabine/Nab-paclitaxel	2	1	0	0	2	2	NS
FOLFIRINOX	5	2	1	1	4	3	NS
Other	10	5	5	6	5	4	NS
None	8	4	8	9	0	0	NS
Site of metastases	(N = 235)		(N = 132)		(N = 103)
Liver	132	57	70	53	63	61	NS
Peritoneum	55	23	35	27	20	19	NS
Lymph nodes	37	16	22	17	15	15	NS
Other	10	4	5	4	5	5	NS

¹Mann-whitney test.

FOLFIRINOX: Folinic acid/fluorouracil/irinotecan/oxaliplatin; NS: Not significative.

Table 2 Tumor response, n (%)

	mEHT	n = 87	no-mEHT	n = 111	P value
PR	39	45	27	24	0.0018
SD	44	51	50	45	0.8430
PD	4	4	34	31	< 0.001

PR: Partial response; PD: Progression disease; SD: Stable disease; mEHT: Modulated electro-hyperthermia.